ribavirin has been researched along with Disease Exacerbation in 253 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 13 (5.14) | 18.2507 |
2000's | 121 (47.83) | 29.6817 |
2010's | 118 (46.64) | 24.3611 |
2020's | 1 (0.40) | 2.80 |
Authors | Studies |
---|---|
Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
Avram, L; Craciun, R; Crisan, D; Crisan, N; Epure, F; Grigorescu, M; Grigorescu, MD; Leach, N; Lupsor, M; Radu, C; Suciu, A | 1 |
Khalili, JS; Mak, NSA; Yan, Y; Zhu, H; Zhu, Y | 1 |
Carmona-Soria, I; Caunedo-Alvarez, A; Cordero-Ruiz, P; Flores-Cucho, A; Quezada-Pacheco, RH; Rodríguez-Téllez, M; Romero-Gómez, M; Vilches-Arenas, Á | 1 |
Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP | 1 |
Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A | 1 |
Hoan, NX; Meyer, CG; Song, LH; Tong, HV; Velavan, TP | 1 |
Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A | 1 |
Chang, F; Duan, CA; Jin, X; Lu, Y | 1 |
Chang, Y; Cho, EJ; Cho, H; Cho, YY; Hwang, SG; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Lee, YB; Nam, JY; Yoon, JH; Yu, SJ | 1 |
Bair, MJ; Chen, HL; Cheng, CH; Chu, CY; Lee, YK; Lin, IT; Wu, CH | 1 |
Bladé, JS; Boudin, L; de Jauréguiberry, JP; Patient, M; Roméo, E; Tsitsi Nding Tsogou, P | 1 |
Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Díez, C; Fanciulli, C; Garcia-Broncano, P; Jiménez-Sousa, MA; Medrano, LM; Miralles, P; Pérez-Latorre, L; Resino, S | 1 |
Abdo, AA; Al-hamoudi, W; Alfaleh, A; Alfaleh, FZ; Ali, SM; Alswat, K; Bedewi, MA; El-sharkawy, M; Hadad, Q; Helmy, A; Omar, M; Shalaby, A | 1 |
Cariti, G; Ceretto, S; Ciancio, A; Ciccone, G; Colletta, C; De Blasi, T; Giordanino, C; Grasso, A; Marenco, S; Mazzucco, D; Picciotto, A; Pirisi, M; Rizzetto, M; Sacco, M; Saracco, G; Simondi, D; Smedile, A; Smirne, C; Traverso, A | 1 |
Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kakinuma, S; Kurosaki, M; Muraoka, M; Nakagawa, M; Nakanishi, H; Nishimura, T; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Watanabe, M; Yasui, Y | 1 |
Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strasser, M; Trauner, M; Wrba, F | 1 |
Del Rio Martin, J; Fiel, MI; Satapathy, SK; Schiano, TD; Vanatta, JM | 1 |
Dultz, G; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kronenberger, B; Sarrazin, C; Seelhof, M; Teuber, G; Vermehren, J; von Wagner, M; Welker, MW; Zeuzem, S | 1 |
Arakawa, Y; Higuchi, T; Matsumura, H; Moriyama, M; Nakamura, H; Nirei, K; Ogawa, M; Tanaka, N | 1 |
Blázquez-Pérez, A; Mar, J; San Miguel, R | 1 |
Brahm, J; Torres, C; Venegas, M | 1 |
Rakela, J; Unzueta, A | 1 |
Galle, PR; Grambihler, A; Kittner, JM; Koch, S; Schattenberg, JM; Schuchmann, M; Thieringer, F; Weinmann, A; Weiss, NM; Wiltink, J; Zimmermann, T | 1 |
Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Sánchez-Parra, C; Soriano, V; Treviño, A; Vispo, E | 1 |
Barluenga, E; Clotet, B; Jou, A; López, JJ; Muga, R; Ojanguren, I; Planas, R; Sanmartín, R; Sanvisens, A; Tor, J; Tural, C; Videla, S | 1 |
Ahmed, AI; Aziz, IA; Bahnasy, KA; Fathelbab, IF; Hafez, TA; Kamal, SM; Kassim, SK; Mahmoud, S; Mansour, HM | 1 |
Kang, W; Lu, Y; Sun, Y; Tong, HI | 1 |
Hui, DS; Memish, ZA; Zumla, A | 1 |
Müllhaupt, B; Rampini, SK; Schaffstein, S | 1 |
Boots, JM; de Man, R; de Vries, MA; Samijn, JP | 1 |
Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E | 1 |
Blunn, A; Chitturi, S; Farrell, G; Kaye, G; Rodrigo, K; Rodriguez-Morales, I; Shadbolt, B; Teoh, N; To, C; Wu, JY | 1 |
Duvnjak, M; Kurelac, I; Vince, A | 1 |
Hrstić, I; Ostojić, R | 1 |
Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Montes, M; Quereda, C; Santos, I; Sanz, J; Téllez, MJ; Von Wichmann, MA; Zamora, FX | 1 |
Ahn, SH; Baatarkhuu, O; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Moon, C; Park, JY | 1 |
Bielsa Marsol, I; Carrascosa Carrillo, JM; Ferrándiz Foraster, C; López Escartin, D; Masnou Ridaura, H; Morillas Cunill, R; Plana Pla, A; Planas Vilà, R; Toro Montecinos, M; Vilavella Rius, M | 1 |
Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS | 1 |
Bargach, T; Chatioui, S; Elasri, F; Iferkhass, S; Khoyaali, A; Oubaaz, A; Reda, K | 1 |
Gerlei, Z; Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Rókusz, L; Szalay, F; Telegdy, L; Tornai, I; Werling, K | 1 |
Cerri, K; Kuwabara, H; Mahlich, J; Treur, M; Westerhout, K; Yatsuhashi, H | 1 |
Chi, B; Li, M; Liu, DW; Wang, J; Wu, XX; Zheng, H | 1 |
Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH | 1 |
Hirohashi, K; Kanazawa, A; Kubo, S; Tanaka, S; Uenishi, T; Yamamoto, T | 1 |
Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC | 1 |
Al Marzooqi, SH; Feld, JJ | 1 |
Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD | 1 |
Athanasakis, K; Ferrante, SA; Hill, M; Kyriopoulos, II; Kyriopoulos, J; Petrakis, I; Retsa, MP | 1 |
Ahmad, J; Bach, N; Chang, C; Chernyiak, M; Doucette, JT; Fiel, MI; Florman, SS; Grewal, P; Khaitova, V; Kim-Schluger, L; Lim, KB; Liu, L; Odin, J; Perumalswami, P; Schiano, TD; Sima, HR | 1 |
Charlton, MR; Dhanasekaran, R; Mounajjed, T; Sanchez, W; Watt, KD; Wiesner, RH | 1 |
Akhtar, M; Gititu, E; Jalluri, C; Ramirez, J; Wilkins, T | 1 |
Gissel, C; Götz, G; Mahlich, J; Repp, H | 1 |
Baba, N; Ikeda, F; Iwasaki, Y; Miyake, Y; Moritou, Y; Nagano, T; Nanba, S; Nouso, K; Ohnishi, H; Seki, H; Senoh, T; Takaguchi, K; Takaki, A; Takeuchi, Y; Yamamoto, K; Yasunaka, T | 1 |
Algendy, D; Amin, M; Elbadry, A; Esmat, S; Fawzi, M; Foda, A; Gabal, S; Kamal, M; Naga, M; Rashed, L; Sabry, D | 1 |
Calvaruso, V; Craxì, A | 1 |
Hézode, C | 1 |
Serfaty, L | 1 |
Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF | 1 |
Goto, H; Hayashi, K; Hirai, T; Honda, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Tachi, Y | 1 |
Cammà, C; Damele, F; Marcellusi, A; Mennini, FS; Taliani, G; Viti, R | 1 |
Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
Castelli, F; Di Filippo, E; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Gagliardini, R; Gori, A; Maggiolo, F; Pan, A; Postorino, MC; Prosperi, M; Quiros Roldan, E; Saracino, A; Sighinolfi, L; Torti, C | 1 |
Choi, JW; Hong, SH; Jang, JW; Kim, DY; Kim, I; Kim, W; Lee, D; Lee, JI; Paik, YH; Yoon, KT | 1 |
Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Ng, KJ; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF | 1 |
Bae, SH; Cho, SB; Jang, ES; Jeong, SH; Kim, IH; Kim, YS; Lee, HC; Lee, YJ; Ok, KS | 1 |
Fortune, BE; Lim, JK; McCarty, TR; Njei, B | 1 |
Heger, E; Inden, S; Kaiser, R; Kalaghatgi, P; Knops, E; Neumann-Fraune, M; Schübel, N; Sierra, S | 1 |
Antosik, D; Barcińska, D; Bereszyńska, I; Januszkiewicz-Lewandowska, D; Kałużna, E; Mozer-Lisewska, I; Nowak, J; Rembowska, J; Strauss, E; Świątek-Kościelna, B; Wysocki, J | 1 |
Albillos, A; Arenas, J; Badia, E; Baliellas, C; Blé, M; Buti, M; Calleja, JL; Carrión, JA; Castells, L; Crespo, J; de la Mata, M; Fernández Bermejo, M; Fernández Carrillo, C; Fernández, I; Fernández-Rodriguez, C; García-Samaniego, J; Granados, R; Herrero, JI; Lens, S; Llop, E; Mariño, Z; Moreno-Palomares, JJ; Moreno-Planas, JM; Pascasio, JM; Pons, C; Prieto, M; Romero, M; Salcedo, M; Salmerón, J; Turnes, J | 1 |
Eason, J; Lipscomb, J; Nair, S | 1 |
Bärthel, E; Habrecht, O; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
Czerwionka-Szaflarska, M; Figlerowicz, M; Gronkowska, A; Kupś, J; Liberek, A; Pawłowska, J; Szaflarska-Popławska, A; Woźniakowska-Gesicka, T; Łoś-Rycharska, E | 1 |
Bailey, KW; Furuta, Y; Gowen, BB; Hall, JO; Jung, KH; Morrey, JD; Smee, DF; Stevens, JR; Wong, MH | 1 |
Antonini, T; Canfora, ML; Castaing, D; Delvart, V; Duclos-Vallee, JC; Roche, B; Roque-Afonso, AM; Saliba, F; Samuel, D; Sebagh, M | 1 |
Hartwell, D; Shepherd, J | 1 |
Pozza, R | 1 |
Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
Abbati, G; Belussi, F; Bonetto, S; Boninsegna, S; Borghi, A; Carbonieri, A; Corradini, E; Fagiuoli, S; Fattovich, G; Felder, M; Ferrara, F; Ferrari, C; Guido, M; Massari, M; Minola, E; Orlandini, A; Pietrangelo, A; Pozzato, G; Rizzo, G; Rossi, E; Rovere, P; Sardini, C; Tagliazucchi, M; Toniutto, P; Vegetti, A; Ventura, P; Zeneroli, ML | 1 |
Bergamaschi, D; Focaccia, R; Patzina, R; Prado, K | 1 |
Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Hoefs, JC; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Sterling, RK | 1 |
Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I | 1 |
Asjø, B; Myrmel, H; Ulvestad, E | 1 |
Berg, T; Böcker, U; Bugert, P; Gundt, J; Haas, SL; Singer, MV; Weiss, C; Witt, H | 1 |
Szaflarska-Popławska, A; Łoś-Rycharska, E | 1 |
Gomes, R; Lee, C; Manka, C; Reviere, R | 1 |
Berenguer, J; Girón, JA; González-Serrano, M; Iribarren, JA; Japón, MA; López-Cortés, LF; Macías, J; Mira, JA; Miralles, P; Moreno, A; Ortega, E; Pineda, JA; Rivero, A | 1 |
Babany, G; Canva-Delcambre, V; Deltenre, P; Deuffic-Burban, S; Dharancy, S; Lonjon-Domanec, I; Louvet, A; Mathurin, P; Roudot-Thoraval, F | 1 |
Alaeus, A; Blom, KG; Falconer, K; Gonzalez, VD; Laursen, AL; Mørn, B; Reichard, O; Sandberg, JK; Weis, N | 1 |
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Naishadham, D; Shiffman, ML; Wright, EC | 1 |
Almerighi, C; Angelico, M; Anselmo, A; De Luca, L; Lenci, I; Lionetti, R; Monaco, A; Palmieri, G; Tariciotti, L; Tisone, G | 1 |
Bruno, S; Gane, EJ; Hadziyannis, SJ; Marcellin, P; Messinger, D; Roberts, SK; Shiffman, ML | 1 |
Galdame, O; Jorge, A; Sordá, J | 1 |
González Ballerga, E; Levi, D; Reggiardo, V | 1 |
Bruix, J; Forns, X | 1 |
Chang, HH; Chen, IM; Shih, CC; Wang, BY; Yang, AH | 1 |
Berenguer, M; Rubin, A | 1 |
Hunt, DR; McClune, A; Saab, S; Stone, MA; Tong, MJ | 1 |
Gutierrez, J; Issacson, RS; Koppel, BS | 1 |
Bonkovsky, HL; De Santo, JL; Di Bisceglie, AM; Dienstag, JL; Ghany, MG; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Snow, KK | 1 |
Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Goodman, ZD; Lok, AS; Naishadham, D; Sterling, RK; Su, GL; Wright, EC | 1 |
Archimandritis, AJ; Giannaris, M; Koskinas, J; Malaktari, S; Papakostas, N; Savvas, SP | 1 |
Lerias de Almeida, PR | 1 |
Bakulin, IG; Iakovleva, EV; Moliarenko, EV; Sharabanov, AS | 1 |
Banner, D; Fang, Y; Farooqui, A; Huang, SS; Kelvin, AA; Kelvin, DJ; Ng, DC; Rowe, T; Rubino, S | 1 |
Ghany, MG; Seeff, LB | 1 |
Akıncı, E; Bayazıt, N; Bodur, H; Erbay, A; Eren, SS; Kubar, A; Öngürü, P | 1 |
Chiba, T; Egawa, H; Haga, H; Hatano, E; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ogura, Y; Oike, F; Takada, Y; Ueda, Y; Uemoto, S; Yoshizawa, A | 1 |
Lawson, A | 1 |
Abd el-Meguid, M; Anany, MA; Bader el-Din, NG; Barakat, A; el-Awady, MK; el-Zayady, AR; Esmat, G; Helmy, A; Tabll, AA; Zayed, N | 1 |
Alter, HJ; Haynes-Williams, V; Heller, T; Herrine, SK; Hoofnagle, JH; Liang, TJ; Loomba, R; McBurney, R; Park, Y; Rehermann, B; Rivera, MM | 1 |
Fukuda, K; Haruna, Y; Hayashi, N; Hiramatsu, N; Hosui, A; Imai, Y; Inoue, A; Inoue, Y; Kanto, T; Kasahara, A; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yoshida, Y | 1 |
Fujise, K; Namiki, Y; Tada, N; Tsubota, A | 1 |
De Vincentiis, L; Durante-Mangoni, E; Iossa, D; Pinto, D; Ragone, E; Utili, R | 1 |
Grotzinger, K; Poordad, F; Sullivan, J; Theodore, D | 1 |
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Lee, WM; Morgan, TR; Morishima, C; Seeff, LB; Shiffman, ML; Snow, KK; Stoddard, AM; Wright, EC | 1 |
Abdullah, NA; Amr, KS; El-Batae, HE; Elhosary, YA; Ezzat, WM; Raslan, HM | 1 |
Masarone, M; Persico, M | 1 |
Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinnuma, S; Kurosaki, M; Matsuura, K; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A | 1 |
Dienstag, JL; Goodman, ZD; Hoefs, JC; Kleiner, DE; Shiffman, ML; Stoddard, AM | 1 |
Aghemo, A; Colombo, M; D'Ambrosio, R; de Franchis, R; De Nicola, S; Dell'Era, A; Donato, MF; Lampertico, P; Prati, GM; Primignani, M; Rumi, MG | 1 |
Desenclos, JC; Deuffic-Burban, S; Dhumeaux, D; Larsen, C; Mathurin, P; Pol, S; Roudot-Thoraval, F; Yazdanpanah, Y | 1 |
Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Litman, HJ; Lok, AS; Sterling, RK; Su, G | 1 |
Kim, R; McEwan, P; Townsend, R; Yuan, Y | 1 |
Roche, B; Samuel, D | 1 |
Chien, CH; Chien, RN; Hu, CC; Kuo, YL; Lin, CL; Lin, CY; Tien, HC; Weng, CH; Yen, CL | 1 |
Ceauşu, E; Gheorghe, L; Iliescu, L; Mateescu, B; Micu, L; Mocan, T; Pascu, O; Seicean, A; Voiculescu, M | 1 |
Cipriano, LE; Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Owens, DK | 1 |
Alberti, AB; Belli, LS; Burra, P; Burroughs, AK; Cillo, U; De Carlis, L; De Martin, E; Fagiuoli, S; Graziadei, I; Gridelli, B; Guido, M; Lerut, J; Pasulo, L; Pinzello, G; Starkel, P; Vogel, W; Volpes, R | 1 |
Ford, JA; Greanya, E; Partovi, N; Wilby, KJ; Yoshida, EM | 1 |
Naggie, S; Sulkowski, MS | 1 |
Avery, R; Budev, M; Danziger-Isakov, L; Li, L; Mossad, S | 1 |
Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Naishadham, D; Shiffman, ML; Szabo, G; Wright, EC | 1 |
El Saadany, S; Enaba, M; Ghazy, M; Hasan, A; Ziada, DH | 1 |
Andreone, P; Bertuzzo, VR; Cescon, M; Cucchetti, A; D'Errico-Grigioni, A; Dazzi, A; Del Gaudio, M; Di Gioia, P; Ercolani, G; Lorenzini, S; Morelli, MC; Pinna, AD; Ravaioli, M; Tamè, M | 1 |
Buti, M; Deltenre, P; Deuffic-Burban, S; Hatzakis, A; Mathurin, P; Moreno, C; Mühlberger, N; Parkes, J; Rosenberg, W; Siebert, U; Stroffolini, T; Zeuzem, S | 1 |
Bahra, M; Boas-Knoop, S; Eurich, D; Kiessling, A; Neuhaus, P; Neuhaus, R; Neumann, UP; Puhl, G; Trautwein, C; Wasmuth, H; Yahyazadeh, A | 1 |
Chuang, WL; Dai, CY; Huang, JF; Yu, ML | 1 |
Cai, W; Fu, Y; Guo, P; Hu, F; Qin, A; Tang, X; Xu, M; Yan, D; Yang, Q; Zhou, J | 1 |
Karatapanis, S; Lisgos, P; Papastergiou, V; Prodromidou, K; Pselas, C; Stampori, M | 1 |
García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
Delahooke, TE; Hayes, PC; Kilpatrick, DC; Koch, C; Turner, ML | 1 |
Panitch, HB | 1 |
Blazek, J; Eason, J; Khan, S; Lipscomb, J; Loss, G; Mason, A; Nair, S | 1 |
Grangé, JD | 1 |
Avendano, M; Booth, CM; Cescon, DW; Chenkin, JS; Derkach, P; Detsky, AS; Dwosh, HA; Ephtimios, IE; Gold, WL; Hawryluck, LA; Kitai, I; Matukas, LM; Mazzulli, T; Mederski, BD; Poutanen, SM; Rachlis, AR; Rea, E; Rose, DB; Shadowitz, SB; Tomlinson, GA; Walmsley, SL | 1 |
Hara, S; Hayashi, N; Hoshino, Y; Hosoya, M; Kajita, Y; Kimura, H; Morisima, T; Nakayama, T; Negoro, T; Okumura, A; Sakuma, T; Tomoda, A | 1 |
Goldie, SJ; Hammitt, JK; Salomon, JA; Weinstein, MC | 1 |
Levenson, D | 1 |
Banks, A; Castro, O; Giday, S; Hasan, S; Hassan, M; Smoot, D | 1 |
Duncan, M; Younossi, Z | 1 |
Braun, M; Vierling, JM | 1 |
Davis, GL | 1 |
Busuttil, RW; Saab, S | 1 |
Copley, L | 1 |
Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
Akbayram, S; Ataş, B; Caksen, H; Odabaş, D; Tepebaşili, I | 1 |
Parini, S | 1 |
Beersma, MF; Bredius, RG; Claas, EC; Heemskerk, B; Kroes, AC; Lankester, AC; Schilham, MW; van Tol, MJ | 1 |
Bernstein, DE; Cheinquer, H; Cooksley, G; Craxi, A; Foster, GR; Green, J; Hassanein, TI; Jensen, DM; Klaskala, W; Lee, SS; Patel, KK; Pettit, K; Sullivan, SD | 1 |
Pearlman, BL | 1 |
Charlton, M; Wiesner, R | 1 |
Yamada, G | 1 |
Teruya, K | 1 |
Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Mariuzzi, L; Minisini, R; Pirisi, M; Toniutto, P | 1 |
Anselmi, E; Arcaini, L; Arcari, AL; Bernuzzi, P; Bertè, R; Callea, V; Cavanna, L; Lazzarino, M; Lazzaro, A; Marasca, R; Moroni, C; Sacchi, S; Trabacchi, E; Vallisa, D | 1 |
Alberti, A | 1 |
Molleston, JP; Rao, GS | 1 |
Afdhal, N; Kelleher, TB | 1 |
Blanco, JL; Forns, X; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J; Sánchez-Tapias, JM | 1 |
Karpov, SIu; Krel', PE | 1 |
Jabłonowska, E | 1 |
Bassendine, M; DeAngelis, D; Grieve, R; Main, J; Roberts, J; Rosenberg, W; Sweeting, M; Thomas, H; Wright, M | 1 |
Alvarez Delgado, A; Fuertes Martín, A; Pérez García, ML | 1 |
Chang, WY; Chuang, WL; Dai, CY; Yu, ML | 1 |
Tien, PC | 1 |
Garcia-Samaniego, J; Maida, I; Martin-Carbonero, L; Nuñez, M; Soriano, V | 1 |
Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P | 1 |
Ostojić, R | 1 |
Bankuti, C; Donnerer, J; Grahovac, M; Kessler, HH; Stadlbauer, V; Stauber, RE; Stelzl, E | 1 |
Blotner, S; Diago, M; Farci, P; Gane, E; Lardelli, P; O'Brien, CB; Pockros, P; Prati, D; Rajender Reddy, K; Shiffman, ML; Zeuzem, S | 1 |
Dieterich, DT; Park, JS; Saraf, N | 1 |
Atripaldi, L; Bellopede, P; Conca, P; Patarino, T; Perrella, A; Perrella, O; Ruggiero, L; Sbreglia, C; Sorrentino, P; Tarantino, G | 1 |
Lawson, A; Ryder, SD | 1 |
Bilusic, M; Hrstic, I; Huic, D; Vucelic, B | 1 |
Ruiz-Sancho, A; Soriano, V | 1 |
Bräu, N; Dieterich, DT; Green, J; Hornberger, J; Patel, K; Sulkowski, MS; Torres, MR; Torriani, FJ | 1 |
Bejarano, PA; Casanova-Romero, PY; Martinez, EJ; Mindikoglu, AL; Regev, A; Schiff, ER; Tzakis, AG | 1 |
Chen, CH; Eng, HL; Hu, TH; Hung, CH; Kuo, FY; Lee, CM; Lu, SN; Wang, JH | 1 |
Bärthel, E; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
Burioni, R; Carletti, S; Clementi, M; Craxì, A; Craxì, RD; Mancini, N; Perotti, M; Romanò, L; Zanetti, AR | 1 |
Arora, N; Goyal, A; Kumar, GT; Sarin, SK; Shukla, DK; Suneetha, PV | 1 |
Andrade, Z; Codes, L; Cruz, M; de Freitas, LA; Paraná, R; Schinoni, MI; Trepo, C | 1 |
Hagiwara, H; Haruna, Y; Hayashi, N; Hijioka, T; Hiramatsu, N; Ishibashi, K; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kubota, S; Kurashige, N; Mita, E; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tsuda, N; Yakushijin, T; Yoshihara, H | 1 |
Blum, HE; Moradpour, D | 1 |
Boix-Martínez, V; Clemente-Ricote, G; Marco-Mouriño, A; Núñez-Martínez, O; Portilla-Sogorb, J; Reus-Bañuls, S; Saiz de la Hoya-Zamácola, P; Teixidó i Pérez, N | 1 |
Asselah, T; Belghiti, J; Boudjema, H; Durand, F; Francoz, C; Marcellin, P; Sobesky, R; Valla, D | 1 |
Back-Madruga, C; Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Gretch, DR; Kulig, CC; Malet, PF; Morgan, TR; Snow, KK; Sterling, RK | 1 |
Addario, L; Ascione, A; Calise, F; Cuomo, O; De Luca, M; Di Costanzo, GG; Lampasi, F; Lanza, AG; Marsilia, GM; Picciotto, FP; Tartaglione, MT; Tritto, G | 1 |
Aikaterini, T; Barbara, M; Claudio, I; Daniela, C; Danila, C; Davide, P; Gaetano, B; Giuseppe, A; Luca, I; Luciano, C; Massimo, L; Salvatore, T; Sergio, N; Stefano, C | 1 |
Alves de Mattos, A; Ferrari de Oliveira Rigo, J; Galperim, B; Lerias de Almeida, PR; Ribeiro de Souza, A; Riegel Santos, B; Valle Tovo, C | 1 |
Korochkina, OV; Sobchak, DM; Sobolevskaia, OL | 1 |
Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Padmanabhan, L; Shiffman, ML | 1 |
Bahra, M; Berg, T; Jacob, D; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, UP | 1 |
Franchini, M | 1 |
Mátyus, J; Tornai, I | 1 |
Duggan, AE; Duggan, JM | 1 |
Assy, N; Embon, O | 1 |
Asselah, T; Boyer, N; Marcellin, P; Martinot, M; Ripault, MP | 1 |
Bosch, J; Bruguera, M; Carrión, JA; Crespo, G; Forns, X; García-Pagan, JC; García-Retortillo, M; Navasa, M | 1 |
Danehower, S; Ghany, MG; Hoofnagle, JH; Liang, TJ; Lutchman, G; Song, BC; Thomson, M | 1 |
Benhamou, Y; Sulkowski, MS | 1 |
Arraes, LC; Crovella, S; Montenegro de Melo, F; Moura, P; Santos Silva, B; Segat, L; Silva Vasconcelos, LR | 1 |
Lunel-Fabiani, F | 1 |
Hollander, A; Jönsson, B; Lidgren, M; Weiland, O | 1 |
Agarwal, K; Emre, S; Fiel, MI; Kontorinis, N; Schiano, TD; Stanca, CM | 1 |
Berkan, E; Jozefowicz-Korczynska, M; Piekarska, A; Wojcik, K | 1 |
Akazawa, K; Aoyagi, Y; Kobayashi, K; Nakamura, J; Toyabe, S | 1 |
Alagna, L; De Bona, A; Galli, L; Gallotta, G; Guzzo, A; Lazzarin, A; Uberti-Foppa, C | 1 |
Lengyel, G; Tulassay, Z | 1 |
Bassett, ML | 1 |
Adachi, Y; Araki, J; Fujita, N; Horiike, S; Iwasa, M; Kaito, M; Kobayashi, Y; Mifuji, R; Sugimoto, R; Tanaka, H; Urawa, N; Yamamoto, M | 1 |
Buzatu, E; Cooper, CL; Dudas, J; Esguerra, R; Gorrell, MD; Haber, PS; Hilzenrat, N; Ionescu, C; Leo, MA; Lieber, CS; McCaughan, GW; Neuman, MG; Ramadori, G; Saile, B; Seth, D; Sha, K; Voiculescu, M; Winkler, RE; Wyse, J; Zakhari, S | 1 |
Afdhal, NH; Brinkley, SC; de Oca, RM; Higgins, Y; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL; Torbenson, MS | 1 |
Alvarez, E; Bellón, JM; Berenguer, J; Castillo, I; Cosín, J; López, JC; Miralles, P; Padilla, B; Resino, S; Sánchez Conde, M | 1 |
Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; De Boever, CM; Halfon, P; Lapidus, N; Perronne, C; Pol, S | 1 |
Najm, W | 1 |
Sharara, AI | 1 |
Brown, JL | 1 |
Delwaide, J | 1 |
Pol, S; Zylberberg, H | 1 |
Wright, TL | 1 |
Patrick, L | 1 |
Barnes, E; Dusheiko, G; Jacobs, R; Webster, G | 1 |
Bjøro, K; Frøland, SS; Haaland, T; Skaug, K | 1 |
Lawrence, SP | 1 |
Dieterich, DT | 1 |
Benhamou, Y; Poynard, T; Ratziu, V; Regimbeau, C | 1 |
Albrecht, J; Bedossa, P; Davis, GL; Esteban-Mur, R; Goodman, Z; McHutchison, J; Poynard, T | 1 |
Bastani, B; Philipneri, M | 1 |
Berk, BS; Chou, S; Corless, CL; Gopal, DV; Olyaei, A; Orloff, SL; Rabkin, JM; Rosen, HR | 1 |
Agarwal, K; Bassendine, DR; Bassendine, MF; Burt, AD; Craig, W; Gilvarry, E; Hewett, M; Jowett, SL; Smith, BC | 1 |
Dieterich, D | 1 |
Norton, M | 1 |
Sulkowski, MS | 1 |
Seeff, LB; Strader, DB | 1 |
Lauer, GM; Walker, BD | 1 |
Anderlini, P; Champlin, RE; Ghosh, S; Jacobson, K; Kontoyiannis, D; Luna, M; Raad, I; Rolston, K; Tarrand, J; Ueno, NT; Whimbey, E | 1 |
Ramrakhiani, S; Sponseller, CA | 1 |
Esteban, JI; Juárez, A; Sauleda, S | 1 |
79 review(s) available for ribavirin and Disease Exacerbation
Article | Year |
---|---|
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Progression; Drug Administration Schedule; Gene Expression Regulation, Viral; Humans; Pandemics; Pneumonia, Viral; Ribavirin; RNA, Viral; SARS-CoV-2; Signal Transduction | 2020 |
Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sustained Virologic Response; Viral Load; Vitamin D; Vitamin D Deficiency | 2018 |
Hepatitis E infection in liver transplant recipients.
Topics: Animals; Chronic Disease; Disease Progression; Feces; Fibrosis; Food Microbiology; Hepatitis E; Humans; Immunosuppression Therapy; Interferons; Liver; Liver Failure; Liver Transplantation; Ribavirin; RNA, Viral | 2014 |
Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.
Topics: Anti-Retroviral Agents; Comorbidity; Disease Management; Disease Progression; End Stage Liver Disease; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.
Topics: Age Distribution; Animals; Antiviral Agents; Camelus; Chiroptera; Coronavirus; Coronavirus Infections; Cross Infection; Diagnosis, Differential; Disease Progression; Female; Humans; Immunity, Innate; Infectious Disease Incubation Period; Interferons; Lung; Male; Middle East; Mycophenolic Acid; Public Health; Radiography; Real-Time Polymerase Chain Reaction; Ribavirin; Severe Acute Respiratory Syndrome; Sex Distribution; Viral Load | 2014 |
[Therapy of chronic hepatitis C].
Topics: Adult; Algorithms; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Polyethylene Glycols; Prognosis; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2014 |
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.
Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].
Topics: Adult; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2013 |
[Treatment of non-1 genotype chronic hepatitis C patients].
Topics: Adult; Age Factors; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin | 2013 |
[Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Optic Atrophy; Optic Neuropathy, Ischemic; Papilledema; Polyethylene Glycols; Radiography; Ribavirin | 2015 |
[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Topics: Antiviral Agents; Consensus; Disease Progression; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Hungary; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome | 2015 |
IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2015 |
Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Risk Assessment; Survival Analysis; Treatment Failure | 2015 |
Diagnosis and Management of Hepatitis C.
Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis Antibodies; Hepatitis C; Humans; Interferon-alpha; Liver Diseases; Mass Screening; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Viral Load; Viral Nonstructural Proteins | 2015 |
Why do I treat my patients with mild hepatitis C?
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin; Treatment Outcome | 2016 |
Why I do not treat patients for mild disease.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin | 2016 |
Follow-up of patients with chronic hepatitis C and a sustained viral response.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2016 |
Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome | 2009 |
Clinical management of HIV/hepatitis C virus coinfection.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Health Services Needs and Demand; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Medication Adherence; Nurse Practitioners; Nurse's Role; Ribavirin; Risk Factors; Severity of Illness Index; Social Support | 2008 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
The hepatitis C virus enigma.
Topics: Antigens, CD; Antiviral Agents; Biological Evolution; Disease Progression; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Receptors, Virus; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Tetraspanin 28; Viral Hepatitis Vaccines; Viremia; Virus Replication | 2009 |
Influence of selected HLA tissue compatibility antigens on the course and efficacy of viral hepatitis C treatment--actual knowledge position.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Evidence-Based Practice; Haplotypes; Hepacivirus; Hepatitis C; HLA Antigens; Humans; Interferons; Major Histocompatibility Complex; Ribavirin; Treatment Outcome | 2009 |
Treatment options for hepatitis C and the rationale for low response rates in African Americans.
Topics: Antiviral Agents; Black or African American; Disease Progression; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ribavirin; Treatment Outcome; United States; White People | 2009 |
Subacute sclerosing panencephalitis: an update.
Topics: Antibodies, Viral; Antiviral Agents; Apoptosis; Brain; Demyelinating Diseases; Disease Progression; Drug Therapy, Combination; Electroencephalography; Epilepsies, Myoclonic; Female; Gliosis; Humans; Inosine Pranobex; Interferon-alpha; Magnetic Resonance Imaging; Male; Measles; Measles Vaccine; Measles virus; Ribavirin; Severity of Illness Index; Sex Factors; Subacute Sclerosing Panencephalitis; Time Factors; Virion | 2010 |
Acute hepatitis C treatment.
Topics: Acute Disease; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Patient Selection; Ribavirin; Treatment Outcome | 2010 |
[Thrombocytopenia in patients with chronic hepatitis C].
Topics: Antiviral Agents; Biomarkers; Disease Progression; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2010 |
Management of untreated and nonresponder patients with chronic hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication | 2010 |
Peginterferon and ribavirin treatment for hepatitis C virus infection.
Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cryoglobulinemia; Disease Progression; Drug Resistance, Viral; Female; Glomerulonephritis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2011 |
Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Models, Economic; Quality-Adjusted Life Years; Ribavirin | 2011 |
Hepatitis C virus treatment pre- and post-liver transplantation.
Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load | 2012 |
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Disease Management; Disease Progression; Drug Interactions; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Glucose abnormalities in hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Ribavirin | 2013 |
Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction.
Topics: Airway Obstruction; Antiviral Agents; Bronchiolitis, Viral; Bronchodilator Agents; Child; Child, Preschool; Disease Progression; Fluid Therapy; Humans; Infant; Infant, Newborn; Oxygen Inhalation Therapy; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Risk Factors; Severity of Illness Index; Virus Replication | 2003 |
[Screening and treatment of acute hepatitis C].
Topics: Acute Disease; Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C; Humans; Interferon-alpha; Mass Screening; Ribavirin; Risk Factors; Treatment Outcome | 2003 |
HCV in sickle cell disease.
Topics: Anemia, Sickle Cell; Antiviral Agents; Chronic Disease; Comorbidity; Disease Progression; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Prevalence; Ribavirin; Transfusion Reaction; United States | 2003 |
Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Recurrence; Retreatment; Ribavirin | 2003 |
The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host.
Topics: Adjuvants, Immunologic; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Interferon-alpha; Liver; Muromonab-CD3; Ribavirin; Transplantation, Homologous | 2003 |
New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation.
Topics: Animals; Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Ribavirin; RNA, Viral; Secondary Prevention; Virus Replication | 2003 |
Practical management of liver transplant recipients for hepatitis C.
Topics: Antiviral Agents; Combined Modality Therapy; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; Treatment Outcome | 2003 |
Viral hepatitis C.
Topics: Adult; Antiviral Agents; Comorbidity; Disease Progression; Enzyme-Linked Immunosorbent Assay; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serotyping; Severity of Illness Index | 2003 |
Hepatitis C treatment update.
Topics: Acute Disease; Adjuvants, Immunologic; Algorithms; Antiviral Agents; Chronic Disease; Decision Trees; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; United States; Viral Load | 2004 |
Natural history and management of hepatitis C infection after liver transplantation.
Topics: Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis].
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid | 2004 |
[Hepatitis C in the HIV-infected person].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Prognosis; Ribavirin; Temperance | 2004 |
Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels.
Topics: Alanine Transaminase; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Liver; Reference Values; Ribavirin | 2005 |
Children with hepatitis C.
Topics: Age Distribution; Antiviral Agents; Child; Child, Preschool; Disease Progression; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Infant; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Sex Distribution | 2005 |
Maintenance therapy for chronic hepatitis C.
Topics: Antiviral Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Long-Term Care; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Analysis; Viral Load | 2005 |
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection].
Topics: Abnormalities, Drug-Induced; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Female; Hematologic Diseases; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Male; Ribavirin | 2005 |
[Clinical characterization and peculiarities of the clinical course of low-activity hepatitis C].
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin | 2005 |
[Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin; Risk Factors | 2004 |
[Treatment of chronic hepatitis C virus infection in human immunodeficiency virus (HIV) infected patients].
Topics: Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain | 2005 |
Treatment of chronic hepatitis C in southern Taiwan.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Species Specificity; Taiwan; Viral Load | 2006 |
New paradigms in the management of HIV and hepatitis C virus coinfection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2005 |
HBV plus HCV, HCV plus HIV, HBV plus HIV.
Topics: Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Disease Progression; Drug Interactions; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2006 |
Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors | 2006 |
[HIV and HCV coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Contraindications; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Multicenter Studies as Topic; Patient Selection; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2006 |
[Therapy of chronic hepatitis C].
Topics: Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention; Treatment Outcome | 2006 |
Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Case Management; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2006 |
[Treatment of hepatitis C in patients on renal replacement therapy].
Topics: Antiviral Agents; Cross Infection; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin | 2007 |
Management of chronic hepatitis C.
Topics: Antiviral Agents; Decision Trees; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin | 2007 |
Therapeutic issues in HIV/HCV-coinfected patients.
Topics: Anemia; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Liver Transplantation; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
[Treatment of recurrent hepatitis C virus infection after liver transplantation].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2007 |
Inflammation and repair in viral hepatitis C.
Topics: Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Risk Factors | 2008 |
Viral hepatitis: how to manage type C and D infections.
Topics: Acute Disease; Aged; Antiviral Agents; Chronic Disease; Disease Progression; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 1997 |
Chronic hepatitis C.
Topics: Antiviral Agents; Blood Transfusion; Carcinoma, Hepatocellular; Cryoglobulinemia; Disease Progression; Forecasting; Genotype; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Porphyria Cutanea Tarda; Ribavirin; Risk Factors; Treatment Outcome | 1997 |
[Update on hepatitis C: potential transmission by invasive medical examinations; new therapeutic modalities (1)].
Topics: Acute Disease; Antiviral Agents; Chronic Disease; Combined Modality Therapy; Cross Infection; Disease Progression; Hepatitis C; Humans; Interferons; Ribavirin | 1998 |
[Interactions between the human immunodeficiency virus and hepatitis C virus].
Topics: Anti-HIV Agents; Antiviral Agents; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prevalence; Ribavirin; Virus Replication | 1998 |
Hepatitis C: epidemiology and review of complementary/alternative medicine treatments.
Topics: Antioxidants; Antiviral Agents; Catechin; Complementary Therapies; Disease Progression; Glycyrrhizic Acid; Hepacivirus; Hepatitis C; Humans; Phytosterols; Plant Extracts; Ribavirin; Silymarin | 1999 |
Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Time Factors | 1999 |
Advances in the treatment of hepatitis C.
Topics: Antiviral Agents; Biopsy; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Failure; Ribavirin | 2000 |
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin | 2000 |
Kidney disease in patients with chronic hepatitis C.
Topics: Antigen-Antibody Complex; Antiviral Agents; Disease Progression; Glomerulonephritis; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Hepatitis C: a brief clinical overview.
Topics: Antiviral Agents; Black People; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Public Health; Remission, Spontaneous; Ribavirin | 2001 |
Hepatitis C virus infection.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver; Liver Transplantation; Prevalence; Ribavirin; Transfusion Reaction | 2001 |
Treatment of hepatitis B and C following liver transplantation.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Resistance; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Interferon-alpha; Lamivudine; Liver Transplantation; Organophosphonates; Prognosis; Ribavirin; Secondary Prevention; Survival Rate | 2002 |
[Treatment of chronic hepatitis C in patients with HIV-coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin | 2002 |
28 trial(s) available for ribavirin and Disease Exacerbation
Article | Year |
---|---|
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate | 2015 |
Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Deoxyguanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron Metabolism Disorders; Leukocytes, Mononuclear; Liver; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oxidative Stress; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors | 2009 |
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load | 2009 |
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2010 |
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; United States | 2010 |
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
Topics: Adult; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2010 |
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome | 2011 |
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
Topics: Antiviral Agents; Disease Progression; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Time Factors; Treatment Outcome | 2011 |
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
Topics: Adipokines; Adult; Chitinase-3-Like Protein 1; Disease Progression; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin | 2012 |
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2012 |
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Treatment Outcome | 2012 |
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load | 2005 |
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Models, Econometric; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; United Kingdom | 2006 |
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Topics: Adult; Amantadine; Antiviral Agents; Disease Progression; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Blood Glucose; Blood Pressure; Body Mass Index; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Metabolic Syndrome; Metabolism; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; RNA, Viral; Sex Factors; Triglycerides | 2006 |
Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Topics: 5' Untranslated Regions; Adult; Antibody Specificity; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Epitopes; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Male; Middle Aged; Molecular Conformation; Neutralization Tests; Polyethylene Glycols; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Envelope Proteins; Viremia | 2006 |
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Health Status; Health Surveys; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 2007 |
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Secondary Prevention; Survival Rate; Treatment Outcome | 2007 |
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Diabetes Mellitus; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors | 2007 |
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Darbepoetin alfa; Disease Progression; Dose-Response Relationship, Drug; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin; Secondary Prevention | 2007 |
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
Topics: Adult; Aged; Antiviral Agents; Cross-Over Studies; Disease Progression; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutagenesis; Ribavirin; Time Factors; Viral Nonstructural Proteins; Viral Proteins | 2007 |
Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
Topics: Adult; Aged; Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Outcome | 2007 |
146 other study(ies) available for ribavirin and Disease Exacerbation
Article | Year |
---|---|
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipase; Liver; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral | 2019 |
Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine | 2018 |
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Topics: Adult; Antiviral Agents; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Markov Chains; Middle Aged; Monte Carlo Method; Polyethylene Glycols; Probability; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Valine | 2018 |
Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response | 2018 |
Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load | 2019 |
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
Topics: Adenine; Aged; Alemtuzumab; Antineoplastic Agents, Immunological; Antiviral Agents; Chronic Disease; Disease Progression; Hepatitis E; Hepatitis E virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Ribavirin | 2019 |
European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Coinfection; Disease Progression; DNA, Mitochondrial; Europe; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk | 2019 |
The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy.
Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin | 2014 |
Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Disease Progression; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral | 2014 |
Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Ascites; Disease Progression; Female; Follow-Up Studies; Hemorrhage; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Withholding Treatment | 2013 |
Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.
Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Ribavirin; Risk Assessment; Risk Factors; Time Factors | 2013 |
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Markov Chains; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain | 2013 |
Lambda interferon serum levels in patients with chronic hepatitis C virus infection according to their response to therapy with pegylated interferon and ribavirin.
Topics: Adult; Biomarkers, Pharmacological; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Immunotherapy; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load | 2014 |
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Decision Making; Disease Progression; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Time Factors; Watchful Waiting | 2014 |
Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Viral Load | 2014 |
Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors | 2014 |
Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.
Topics: Acute Disease; Adult; Age Distribution; Antiviral Agents; Case-Control Studies; Confidence Intervals; Disease Progression; Egypt; Female; GB virus C; Genotype; Hepacivirus; Hepatitis C; Humans; Incidence; Interferons; Interleukins; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribavirin; RNA, Viral; Sex Distribution; Statistics, Nonparametric; Treatment Outcome; Viral Load; Viremia | 2014 |
Hepatitis E-associated encephalopathy in a renal transplant recipient.
Topics: Aged; Biopsy, Needle; Chronic Disease; Disease Progression; Electromyography; Female; Follow-Up Studies; Graft Survival; Hepatic Encephalopathy; Hepatitis E; Humans; Immunocompromised Host; Immunohistochemistry; Kidney Failure, Chronic; Kidney Transplantation; Liver Function Tests; Magnetic Resonance Imaging; Ribavirin; Severity of Illness Index; Transplant Recipients; Transplantation Immunology; Treatment Outcome; Viral Load | 2014 |
Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C.
Topics: Adult; Antiviral Agents; Depression; Disease Progression; Female; Hepatitis C; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Multivariate Analysis; Ribavirin; Schizophrenia | 2014 |
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis.
Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Predictive Value of Tests; Ribavirin; RNA, Viral; Viral Load | 2014 |
Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Protective Factors; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study.
Topics: Adult; Aged; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Severity of Illness Index | 2015 |
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Models, Econometric; Phenotype; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir | 2015 |
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
Topics: Adult; Allografts; Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Genotype; Greece; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Markov Chains; Models, Econometric; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity | 2015 |
Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Topics: Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; New York City; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Virus Activation | 2015 |
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Treatment Outcome; Viral Load | 2015 |
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
Topics: Adult; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Egypt; Exons; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Genetic; Receptors, LDL; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome | 2015 |
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Proportional Hazards Models; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Ultrasonography | 2016 |
α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Remission Induction; Retrospective Studies; Ribavirin; ROC Curve; Severity of Illness Index; Sustained Virologic Response; Time Factors; Treatment Outcome | 2016 |
Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Longitudinal Studies; Male; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome | 2016 |
Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Young Adult | 2016 |
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Topics: Aged; Antiviral Agents; Aspartate Aminotransferases; Blood Platelets; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan | 2016 |
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Republic of Korea; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response | 2016 |
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States | 2016 |
HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine; Viral Nonstructural Proteins | 2017 |
Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome.
Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interleukin-10; Liver; Male; Middle Aged; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2017 |
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Cohort Studies; Disease Progression; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Spain; Survival Analysis; Treatment Outcome | 2017 |
[The analysis of the hepatitis C virus infection course and efficacy of treatment dependence on HLA A antigens in children and youth].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; Hepatitis C; HLA-A Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin | 2008 |
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin.
Topics: Absorption; Administration, Oral; Alanine Transaminase; Amides; Animals; Arenaviridae Infections; Aspartate Aminotransferases; Cricetinae; Disease Models, Animal; Disease Progression; Female; Hemorrhagic Fevers, Viral; Interferon Type I; Liver Diseases; Mesocricetus; Pichinde virus; Pyrazines; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load | 2008 |
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Ribavirin; Secondary Prevention; Treatment Outcome; Young Adult | 2008 |
Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Ferritins; Hemolysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transferrin; Treatment Outcome | 2009 |
Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Romania; Severity of Illness Index; Time Factors; Transaminases; Treatment Outcome; Viral Load | 2009 |
Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-18; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy; Cohort Studies; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors | 2009 |
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Disease Progression; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Young Adult | 2009 |
High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.
Topics: ADP-ribosyl Cyclase 1; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes; Viral Load; Young Adult | 2009 |
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression.
Topics: Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Ribavirin | 2010 |
[Treatment of cirrhotics].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2005 |
[Treatment of patients with normal liver aminotransferases].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases | 2005 |
Treating hepatitis C in patients with cirrhosis: the effort is worth it.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; Treatment Outcome | 2010 |
Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.
Topics: Acute Disease; Antiviral Agents; Autopsy; Disease Progression; Fatal Outcome; Graft Rejection; Heart Transplantation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Time Factors; Transplantation, Homologous | 2010 |
An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Topics: Antiviral Agents; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Markov Chains; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Middle Aged; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Interferon alpha-induced hashimoto thyroiditis followed by transient graves disease in a patient with chronic HCV infection.
Topics: Adult; Antiviral Agents; Autoantibodies; Autoantigens; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Graves Disease; Hashimoto Disease; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Iodide Peroxidase; Iron-Binding Proteins; Male; Polyethylene Glycols; Receptors, Thyrotropin; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells | 2010 |
In vivo ribavirin activity against severe pandemic H1N1 Influenza A/Mexico/4108/2009.
Topics: Animals; Antiviral Agents; Chick Embryo; Disease Models, Animal; Disease Progression; Female; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Orthomyxoviridae Infections; Ribavirin; Survival Analysis | 2010 |
Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Case-Control Studies; Disease Progression; Female; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Humans; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2011 |
Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2012 |
A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asia; Child; Child, Preschool; Disease Progression; Female; Hepatitis C; Humans; Infant; Interferon-beta; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome | 2011 |
Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA, Viral; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Envelope Proteins; Viral Load; Virus Activation | 2011 |
The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2011 |
Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2011 |
Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Echocardiography; Electrocardiography; Female; Genotype; Heart Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Troponin I | 2011 |
Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
Topics: Antiviral Agents; Blood Transfusion; Disease Progression; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Inpatients; Insurance Claim Review; Interferons; Male; Middle Aged; Outpatients; Platelet Count; Regression Analysis; Retrospective Studies; Ribavirin; Thrombocytopenia; United States | 2011 |
Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Disease Progression; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Peptidyl-Dipeptidase A; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Ribavirin | 2011 |
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Decision Trees; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Severity of Illness Index | 2011 |
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Computer Simulation; Disease Progression; Drug Costs; Drug Therapy, Combination; Drug Utilization; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Young Adult | 2012 |
Hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Ribavirin; Viral Hepatitis Vaccines; World Health Organization | 2011 |
Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.
Topics: Administration, Oral; Anemia; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Taiwan | 2012 |
Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Romania; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Medication Adherence; Protease Inhibitors; Quality-Adjusted Life Years; Ribavirin; Risk Factors; Treatment Outcome | 2012 |
Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Female; Humans; Lung Transplantation; Male; Middle Aged; Respiratory Syncytial Virus Infections; Retrospective Studies; Ribavirin; Severity of Illness Index; Survival Rate; Treatment Outcome; Young Adult | 2012 |
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C.
Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Viral Load | 2012 |
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2012 |
Predicted effects of treatment for HCV infection vary among European countries.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Mass Screening; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Ribavirin | 2012 |
YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
Topics: Adipokines; Adult; Antiviral Agents; Chitinase-3-Like Protein 1; Cyclosporine; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lectins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Factors; Statistics, Nonparametric; Tacrolimus; Time Factors; Young Adult | 2013 |
Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Arginase; Cell Count; Disease Progression; Female; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Myeloid Cells; Ribavirin; RNA, Viral; T-Lymphocytes; Young Adult | 2013 |
Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2013 |
Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Seropositivity; Humans; Interferons; Liver Failure; Liver Function Tests; Ribavirin; Risk-Taking; Substance Abuse, Intravenous; Treatment Failure | 2003 |
Mannan-binding lectin and hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Disease Progression; Disease Susceptibility; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Ribavirin | 2003 |
Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit?
Topics: Adult; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure | 2003 |
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antiviral Agents; Biomarkers; Communicable Diseases, Emerging; Comorbidity; Cough; Demography; Disease Outbreaks; Disease Progression; Dyspnea; Female; Fever; Hospitalization; Humans; Hydrocortisone; Infection Control; Intensive Care Units; Lung; Male; Middle Aged; Ontario; Proportional Hazards Models; Radiography; Respiration, Artificial; Retrospective Studies; Ribavirin; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Statistics, Nonparametric; Survival Analysis | 2003 |
Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay.
Topics: Antiviral Agents; Blood; Cerebrospinal Fluid; Child; Disease Progression; Drug Therapy, Combination; Humans; Injections, Intraventricular; Interferon-alpha; Male; Measles virus; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA; RNA, Viral; Subacute Sclerosing Panencephalitis | 2003 |
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Liver Cirrhosis; Male; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States | 2003 |
Some hepatitis C patients -- especially women -- don't really benefit from early therapy.
Topics: Cost-Benefit Analysis; Disease Progression; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Practice Guidelines as Topic; Quality of Life; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; United States; Women | 2003 |
Hepatitis C: treatment challenges.
Topics: Antiviral Agents; Chronic Disease; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Patient Education as Topic; Ribavirin; Treatment Outcome | 2003 |
Report of two children with subacute sclerosing panencephalitis displaying an atypical clinical course.
Topics: Antiviral Agents; Aphasia; Child; Child, Preschool; Disease Progression; Emergency Medicine; Fatal Outcome; Female; Gait Ataxia; Humans; Inosine Pranobex; Interferons; Male; Ribavirin; Subacute Sclerosing Panencephalitis; Treatment Outcome | 2004 |
Hepatitis C: speaking out about the silent epidemic.
Topics: Adaptation, Psychological; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon-alpha; Nurse's Role; Patient Education as Topic; Prevalence; Ribavirin; Risk Factors; United States | 2001 |
Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; DNA, Viral; Humans; Lymphocytes; Prospective Studies; Ribavirin; Stem Cell Transplantation; Treatment Outcome; Viral Load | 2004 |
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; United States; Viral Load | 2004 |
[Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis].
Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; False Negative Reactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases | 2004 |
Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.
Topics: Alleles; Antiviral Agents; Apolipoproteins E; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; History, 16th Century; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Recurrence; Ribavirin | 2004 |
Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2005 |
[Retreatment of patients with chronic hepatitis C].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Retreatment; Ribavirin; Treatment Failure | 2005 |
Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fibrosis; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2005 |
Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
Topics: Alanine Transaminase; Antiviral Agents; Blood Preservation; Chromatography, High Pressure Liquid; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Half-Life; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2006 |
Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms.
Topics: Acute Disease; Adult; Antiviral Agents; Case-Control Studies; CD11 Antigens; Cell Count; Dendritic Cells; Disease Progression; Drug Combinations; Female; Flow Cytometry; Hepatitis A; Hepatitis C; Humans; Interferons; Lipopolysaccharide Receptors; Male; Middle Aged; Myeloid Cells; Ribavirin | 2006 |
Autoimmune disorders during interferon therapy in a patient with chronic hepatitis C infection: how many of them can be observed in a single patient?
Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Disease Progression; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2006 |
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Topics: Age Distribution; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome; United States | 2006 |
The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
Topics: Adult; Antiviral Agents; Biopsy; Cholesterol, HDL; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Liver Cirrhosis; Living Donors; Male; Metabolic Syndrome; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Triglycerides | 2006 |
Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Transplantation, Homologous; Viral Load; Viremia | 2006 |
CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.
Topics: Adult; Alanine Transaminase; Alleles; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Receptors, CCR5; Recombinant Proteins; Ribavirin; Severity of Illness Index | 2006 |
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Autoantibodies; Disease Progression; Drug Therapy, Combination; gamma-Glutamyltransferase; Golgi Apparatus; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2006 |
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2006 |
[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Patient Compliance; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Prisoners; Prisons; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Spain; Substance Abuse, Intravenous; Treatment Outcome | 2006 |
Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin.
Topics: Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opioid-Related Disorders; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Viral Load | 2007 |
Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Viral Load | 2007 |
[Assessment of the values of immune response mediators in patients with acute hepatitis C receiving combined antiviral therapy].
Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Biomarkers; Cytokines; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Immunoenzyme Techniques; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication | 2006 |
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors | 2007 |
Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection.
Topics: Adult; Aged; Antiviral Agents; Brazil; Case-Control Studies; Disease Progression; Exons; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Recent advances in hepatitis C virus research and understanding the biology of the virus.
Topics: Antiviral Agents; Biomedical Research; Disease Progression; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Efficiency; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferons; Male; Markov Chains; Models, Economic; Quality of Life; Ribavirin; Treatment Outcome | 2007 |
Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Survival Rate | 2007 |
Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Audiometry, Pure-Tone; Disease Progression; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Turner Syndrome | 2007 |
The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Markov Chains; Models, Econometric; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2007 |
Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.
Topics: Antiviral Agents; Biomarkers; Child; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Poisson Distribution; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2007 |
Iron and hepatitis C: beginning to make sense.
Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Phlebotomy; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Failure; Treatment Outcome | 2007 |
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Disease Progression; Female; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Incidence; Interferons; Liver; Logistic Models; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Ribavirin | 2007 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nevirapine; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Viral Load | 2008 |
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Mitochondria; Prevalence; Ribavirin; Risk Factors | 2008 |
Efficacy of combined interferon and ribavirin for treatment of hepatitis C.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; Time Factors | 1998 |
Treatment of hepatitis C: a decision that needs careful consideration.
Topics: Antiviral Agents; Disease Progression; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Risk | 1999 |
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.
Topics: Adolescent; Adult; Agammaglobulinemia; Antiviral Agents; Common Variable Immunodeficiency; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin | 1999 |
Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.
Topics: Anti-HIV Agents; Antiviral Agents; Biopsy, Needle; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Ribavirin | 1999 |
[Treatment and prevention of hepatitis C].
Topics: Antiviral Agents; Clinical Protocols; Delayed-Action Preparations; Disease Progression; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Prospective Studies; Ribavirin | 2000 |
Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2001 |
Managing chronic hepatitis C acquired through intravenous drug use.
Topics: Adolescent; Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Patient Compliance; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome | 2001 |
Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James.
Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin; United States; United States Food and Drug Administration | 1998 |
Evolving strategies to attack hepatitis C.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Factors | 1998 |
Hepatitis C virus and HIV co-infection: a sleeping giant wakes.
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 1999 |
Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins.
Topics: Aerosols; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Breast Neoplasms; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Pneumonia, Viral; Respiratory Syncytial Virus Infections; Retrospective Studies; Ribavirin; Survival Rate; Transplantation, Autologous | 2001 |